Warren Center For Neuroscience Drug Discovery
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive, worldwide license and a research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. The licensed program centers around the M4 muscarinic receptor positive allosteric modulator—including… Read MoreFeb. 23, 2022
-
Understanding the molecules and brain circuits recruited by stressful experience
Stressful experiences can lead to adaptive or detrimental behaviors. Understanding how stress can affect our brains can help understand basic brain function and is also essential to discerning causes and treatments for some diseases. A group of researchers led by Jeffrey Conn, professor of pharmacology at… Read MoreFeb. 18, 2022
-
Vanderbilt extends its longest ongoing drug discovery agreement with pharmaceutical company through 2023
Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. The initial agreement was signed in November… Read MoreDec. 22, 2021